standard treatment in these fields. This is the primary challenge of interventional oncology for palliative care worldwide.

Conclusion

Interventional oncology has potential advantages as a better treatment in various fields of oncology because of its features. However, most procedures in interventional oncology have not been recognized as the standard treatment because of lack of firm evidence. Although there are issues in performing clinical trials of interventional oncology, establishment of evidence is critical to making interventional oncology the standard treatment in oncology. Interventional radiologists should know the importance of clinical trials, and should move ahead in this direction in a step-by-step manner.

Acknowledgment This review article was supported in part by a grant-in-aid for cancer research from the National Cancer Center in Japan.

Conflict of interest The author declares that he has no conflict of interest.

References

1. Margulis AR (1967) Interventional diagnostic radiology: a subspeciality. AJR Am J Roentgenol 99:761–762
2. Wallace S (1976) Interventional radiology. Cancer 37:517–531
3. Pons F, Varela M, Llovet JM (2005) Staging systems in hepatocellular carcinoma. HPB (Oxford) 7:35–41
4. ClinicalTrials. Gov. http://clinicaltrials.gov/
5. UMIN-CTR. http://www.umin.ac.jp/
6. Kerr DJ, McArdle CS, Ledermann J et al (2003) Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicenter randomized trial. Lancet 361:368–373
7. Tanaka T, Arai Y, Inaba Y et al (2003) Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 14:63–68
8. Toyoda H, Kumada T, Sone Y (2009) Impact of a unified CT angiography system on outcome of patients with hepatocellular carcinoma. AJR Am J Roentgenol 192:766–774
9. Kobayashi T, Arai Y, Takeuchi Y et al (2009) Phase I/II clinical study of percutaneous vertebroplasty (PVP) as palliation for painful malignant vertebral compression fractures (PMVCF): JIVROSG-0202. Ann Oncol 20:1943–1947
10. Arai Y, Inaba Y, Sone M et al (2011) Phase I/II study of transjugular transhepatic peritoneovenous venous shunt, a new procedure to manage refractory ascites in cancer patients: Japan Interventional Radiology in Oncology Study Group 0201. AJR Am J Roentgenol 196:W621–W626

International Journal of
Radiation Oncology
biology • physics

www.redjournal.org

Clinical Investigation: Pancreatic Cancer

A Multicenter Phase II Trial of S-1 With Concurrent Radiation Therapy for Locally Advanced Pancreatic Cancer

Masafumi Ikeda, MD,* Tatsuya Ioka, MD,† Yoshinori Ito, MD,‡ Naohiro Yonemoto, MPH,§ Michitaka Nagase, MD,|| Kenji Yamao, MD,¶ Hiroyuki Miyakawa, MD, Hiroshi Ishii, MD,†† Junji Furuse, MD,‡‡ Keiko Sato, PhD,§§ Tosiya Sato, PhD,|||| and Takuji Okusaka, MD¶¶**

**Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan; †Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; ‡Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan; §Department of Epidemiology and Biostatistics, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan; ||Department of Clinical Oncology, Jichi Medical University, Tochigi, Japan; ¶Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan; **Department of Gastroenterology, Sapporo Kosei General Hospital, Sapporo, Japan; ††Hepatobiliary and Pancreatic Division, Cancer Institute Hospital, Tokyo, Japan; ‡‡Department of Internal Medicine, Medical Oncology School of Medicine, Kyorin University, Tokyo, Japan; §§Kyoto Unit Center, Japan Environment and Children's Study, Kyoto University Graduate School of Medicine, Kyoto, Japan; ||||Department of Biostatistics, Kyoto University School of Public Health, Kyoto, Japan; and ¶¶Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan*

Received Feb 8, 2012, and in revised form Mar 24, 2012. Accepted for publication Mar 27, 2012

Summary

S-1 is the first single anti-cancer agent to be judged non-inferior to gemcitabine in a large-scale, randomized, phase III trial for advanced pancreatic cancer, and it can also act as a radiosensitizer. S-1 with concurrent radiation therapy showed very favorable activity, with mild toxicity in patients with

Purpose: The aim of this trial was to evaluate the efficacy and toxicity of S-1 and concurrent radiation therapy for locally advanced pancreatic cancer (PC).

Methods and Materials: Locally advanced PC patients with histologically or cytologically confirmed adenocarcinoma or adenosquamous carcinoma, who had no previous therapy were enrolled. Radiation therapy was delivered through 3 or more fields at a total dose of 50.4 Gy in 28 fractions over 5.5 weeks. S-1 was administered orally at a dose of 80 mg/m^2 twice daily on the day of irradiation during radiation therapy. After a 2- to 8-week break, patients received a maintenance dose of S-1 (80 mg/m^2/day for 28 consecutive days, followed by a 14-day rest period) was then administered until the appearance of disease progression or unacceptable toxicity. The primary efficacy endpoint was survival, and the secondary efficacy endpoints were progression-free survival, response rate, and serum carbohydrate antigen 19-9 (CA19-9) response; the safety endpoint was toxicity.

Results: Of the 60 evaluable patients, 16 patients achieved a partial response (27%; 95% confidence interval [CI], 16%-40%). The median progression-free survival period, overall survival period, and 1-year survival rate of the evaluable patients were 9.7 months (95% CI, 6.9-11.6 months),

Reprint requests to: Masafumi Ikeda, MD, Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital E, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. Tel: 81-4-7133-1111; Fax: 81-4-7133-0335; E-mail: masikeda@east.ncc.go.jp

This work was presented in abstract form on June 4-6, 2010. at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

This study was supported in part by grants-in-aid for cancer research from the Ministry of Health, Labor, and Welfare of Japan.

Conflict of interest: none.

Supplementary material for this article can be found at www.redjournal.org.

Int J Radiation Oncol Biol Phys, Vol. 85, No. 1, pp. 163–169, 2013
0360-3016/$ - see front matter
doi:10.1016/j.ijrobp.2012.03.059

locally advanced pancreatic cancer.

16.2 months (95% CI, 13.5-21.3 months), and 72% (95%CI, 59%-82%), respectively. Of the 42 patients with a pretreatment serum CA19-9 level of ≥100 U/ml, 34 (81%) patients showed a decrease of greater than 50%. Leukopenia (6 patients, 10%) and anorexia (4 patients, 7%) were the major grade 3-4 toxicities with chemoradiation therapy.

Conclusions: The effect of S-1 with concurrent radiation therapy in patients with locally advanced PC was found to be very favorable, with only mild toxicity. © 2013 Elsevier Inc.

Introduction

Pancreatic cancer (PC), one of the most lethal human cancers, has become the fifth most common cause of death due to cancer in Japan; it has been estimated that PC was responsible for 26,791 deaths in 2009, representing approximately 3% of all deaths. PC patients have a dismal prognosis, as their 5-year survival after diagnosis is less than 5%. Of all treatment modalities available for PC, only resection offers an opportunity for a cure. However, approximately half of patients already have metastases at the time of diagnosis, and approximately one-third of patients are diagnosed as having locally advanced disease, whereas only a small proportion of patients are eligible for surgery, as a result of the lack of effective screening. Concurrent chemoradiation therapy with external beam radiation therapy and chemotherapy using 5-fluorouracil (5-FU) is often used in patients who have unresectable PC due to vascular involvement that includes the celiac artery or supra-mesenteric artery, with no distant metastases on radiological examination, because it is generally accepted as a standard therapy for locally advanced PC (1-4). A variety of anticancer agents, including gemcitabine (5) and capecitabine (6), and various radiation schedules (7-8) have been examined in clinical trials, but survival has not been significantly improved.

S-1 is a new oral fluoropyrimidine derivative in which tegafur is combined with 2 5-chloro-2,4-dihydroxypyridine modulators and oteracil potassium, a potentiator of 5-FU's antitumor activity that also decreases gastrointestinal toxicity. A multi-institutional, late-phase II trial of S-1 involving metastatic PC patients reported a good tumor response rate (38%) and improved survival (median, 9.2 months) (9). A phase III trial compared therapy with S-1, with gemcitabine alone, and with gemcitabine plus S-1 in patients with unresectable PC in Japan and Taiwan, and S-1 therapy was found to provide efficacy and toxicity similar to gemcitabine when it was used as a first-line treatment for advanced PC (median survival: S-1, 9.7 months; gemcitabine, 8.8 months [hazard ratio, 0.96; non-inferiority P value <.001]); thus, S-1 was judged to be non-inferior to gemcitabine (10). S-1 also acts as a radiosensitizer, and preclinical and clinical studies have demonstrated the radiosensitizing potency of S-1 (11). Not only is S-1 a potent radiosensitizer that has been shown to have promising antitumor activity against advanced PC, but also, since it is active orally, it is also much more convenient for patients than intravenous 5-FU infusion. Thus, concurrent raditation therapy and oral S-1 instead of 5-FU infusion may be a more efficient treatment that also improves patients' quality of life. In a phase I trial conducted in one of our hospitals, the recommended S-1 dose with concurrent radiation therapy was found to be 80 mg/m^2/day on the day of irradiation; at this dose, S-1 was found to have excellent antitumor activity with mild toxicity (12). Consequently, a multi-institutional phase II study was conducted to clarify the efficacy and safety of concomitant radiation therapy with S-1 in patients with locally advanced PC.

Methods and Materials

Patients and eligibility

Patients eligible for study entry had locally advanced nonresectable clinical stage III (T4N0-1 and M0) PC, according to International Union Against Cancer criteria. Eligibility criteria were adenocarcinoma or adenosquamous carcinoma confirmed on cytology or histology; no previous chemotherapy for PC; a square (10 cm × 10 cm) radiation field could encompass all pancreatic lesions and lymph node metastases; age ≥20 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; adequate oral intake; satisfactory hematological functions (hemoglobin concentration, ≥9.0 g/dl; leukocyte count, ≥3500/mm^3; platelet count, ≥100,000/mm^3); adequate hepatic function (serum total bilirubin ≤2.0 times the upper normal limit [UNL] or ≤3.0 mg/dl with biliary drainage); aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤2.5 times UNL or ≤5 times UNL with biliary drainage; serum albumin ≥3.0 g/dl; and normal renal function (serum creatinine ≤UNL). Written informed consent was obtained from all patients.

Exclusion criteria were active infection; active gastroduodenal ulcer; watery diarrhea; phenytoin, warfarin potassium, or flucytosine treatment; pleural effusion or ascites; severe complications such as cardiac or renal disease; psychiatric disorder; history of drug hypersensitivity; and active concomitant malignancy. In addition, pregnant and lactating women and women of childbearing age who were not using effective contraception were also excluded.

Pretreatment evaluation required a complete history and physical examination and baseline assessments of organ function. In addition, contrast medium-enhanced computed tomography (CT) or magnetic resonance imaging of the abdomen and X-ray or CT of the chest was performed for pretreatment staging to assess the local extension of the tumor and to exclude the presence of distant metastases. The criteria for local extension surrounding the pancreas included tumor invasion to the celiac trunk or superior mesenteric artery, or both, which corresponded to clinical stage III according to the International Union Against Cancer (6th edition). All patients with obstructive jaundice underwent percutaneous transhepatic or endoscopic retrograde biliary drainage before treatment. Laparoscopy and laparotomy to rule out occult peritoneal dissemination prior to study entry were not necessary.

Treatment schedule

The regimen consisted of S-1 with concurrent radiation therapy and maintenance S-1 chemotherapy.

S-1 with concurrent radiation therapy

Radiation therapy was delivered with >6-MV photons, using a multiple (three or more) field technique. A total dose of 50.4 Gy

was delivered in 28 fractions over 5.5 weeks. Primary tumor and metastatic lymph nodes >1 cm identified on CT were contoured as gross tumor volumes (GTV). The clinical target volume (CTV) included the primary tumor with a 0.5-cm margin and metastatic lymph nodes. Regional lymph nodes were not treated electively. The definition of planning target volume (PTV) include the CTV with a 1-cm margin laterally and a 1- to 2-cm margin in the craniocaudal direction to take into account respiratory organ motion and daily set-up errors. The reference point for the radiation dose was set at the center of the PTV. The spinal cord dose was maintained at <45 Gy. The volume of liver to receive 30 Gy was required to be <40%, and the volume to receive 20 Gy was required to be <67%. At least 75% of both kidneys was required to receive less than 18 Gy.

S-1 was administered orally at a dose of 40 mg/m^2 twice daily after breakfast and dinner on the day of irradiation (Monday through Friday) during radiation therapy. The 3 initial doses were determined according to the body surface area (BSA) as follows: patients with a BSA of <1.25 m^2 received 40 mg/dose; those with BSA of 1.25 m^2-<1.5 m^2 received 50 mg/dose; and those with BSA of ≥1.5 m^2 received 60 mg/dose. The dose of S-1, which is the standard dose when S-1 is used as a single agent for systemic therapy (15, 16), had been previously determined in our phase I trial (19).

The occurrence of grade 4 hematological toxicity, grade 3 non hematological toxicity excluding nausea, anorexia, fatigue, constipation, and hyperglycemia, or a serum AST or ALT >200 IU/l resulted in the suspension of radiation therapy and S-1 administration. When the toxicities improved by at least 1 grade compared to the suspension criteria, treatment was resumed. When suspension criteria were met, dose modification was allowed as follows: patients with a BSA of <1.25 m^2 received 25 mg/dose; those with a BSA of 1.25 m^2-<1.5 m^2 received 40 mg/dose; and those with a BSA ≥1.5 m^2 received a 50 mg/dose. Chemoradiation therapy was discontinued when the patient developed grade 4 non-hematological toxicities or other unacceptable toxicities, including gastrointestinal ulcer or bleeding, interruptions in treatment of >15 days, or unequivocal tumor progression. After treatment discontinuation, patients could receive other anticancer treatments excluding S-1 with concurrent radiation therapy at their physician's discretion.

Maintenance S-1 chemotherapy

From 2-8 weeks after completion of S-1 with concurrent radiation therapy, maintenance S-1 chemotherapy was initiated at a dose of 40 mg/m^2 twice daily orally, after breakfast and dinner, for 28 consecutive days, followed by a 14-day rest period per course. Treatment cycles were repeated until the appearance of disease progression, unacceptable toxicities, or the patient's refusal to continue treatment. If a grade 3 or higher hematological toxicity or a grade 2 or higher non hematological toxicity was observed, temporary interruption or dose reduction of S-1 administration was allowed as follows: patients with a BSA of <1.25 m^2 received 25 mg/dose; those with a BSA of ≤1.25 m^2-<1.5 m^2 received a 40 mg/dose; and those with a BSA of ≥1.5 m^2 received a 50 mg/dose. When grade 4 non hematological toxicities, unacceptable toxicities, a rest period >28 days, or an unequivocal tumor progression was observed during maintenance S-1 chemotherapy, treatment was discontinued. After treatment discontinuation, patients could be given other anticancer treatment, excluding S-1 monotherapy, at their physician's discretion.

Response and toxicity assessment

Evaluations of tumor response during chemoradiation therapy and maintenance therapy were performed at the completion of chemoradiation therapy and every 6 weeks thereafter until tumor progression or 24 weeks from the start of S-1 and radiation therapy, using the Response Evaluation Criteria in Solid Tumors version 1.0 questionnaire. Responses were evaluated centrally by 3 independent reviewers. Serum carbohydrate antigen 19-9 (CA19-9) levels were measured at least every 6 weeks. In patients with a pretreatment CA19-9 level ≥100 U/ml, the CA19-9 response was assessed; a positive response was defined as a reduction of >50% from the pretreatment level (13). Overall survival was measured from the date of initial treatment to the date of death or the date of the last follow-up. Progression-free survival was defined as the time from the date of initial treatment to the first documentation of progression or death. Basic laboratory tests that included a complete blood count with differentials, serum chemistry, and urinalysis were administered at least weekly during S-1 therapy and radiation therapy and then at least once every 2 weeks during S-1 maintenance therapy. Common Terminology Criteria for Adverse Events, version 3.0, were used for the assessment of treatment-related toxicities.

Radiation therapy quality assurance

All radiation therapy treatment plans for the enrolled patients were reviewed centrally by an independent radiation committee consisting of 9 radiation oncologists. To assess radiation therapy protocol compliance, the following parameters were reviewed: fraction size, prescribed dose to the reference point, energy, relationships between GTV, CTV, PTV and radiation field, overall treatment time, isodose distributions at the transverse section of the reference points, and doses to organs at risk. The quality assurance assessment was given as per protocol (PP), deviation acceptable (DA), and violation unacceptable (VU). After parameter compliance was assessed, overall radiation therapy compliance was classified as: PPoverall, no DA or VU in any parameter; VUoverall, at least 1 VU in any parameter; or DAoverall, neither PP nor VU.

Statistical considerations

Primary endpoints of this trial were overall survival for the efficacy evaluation and frequency of adverse events for the safety evaluation; secondary endpoints were progression-free survival, response rate, and serum CA19-9 level response.

The enrollment goal was set at 60 eligible patients. The number of enrolled patients was determined using a statistical power analysis. Under the assumptions of a median survival time of 10 months for patients receiving conventional chemoradiation therapy (1-4), a 2-year registration period followed by a 2-year follow-up period and a one-sided alpha level of 5%, the statistical power of the hazard ratio test was over 70% or 90% with the expected median survival time of 14 or 16 months, respectively. Therefore, the number of planned enrolled patients, the registration period, the follow-up period, and the total research period were set at 60, 2 years, 2 years, and 4 years, respectively. The full analysis set (FAS) was defined as any patient who received at least 1 course of study medication. Overall and progression-free survival curves were calculated using the Kaplan-Meier method. This open-label, multi-institutional, single arm

phase II study was approved by the review board of each institution and was conducted in accordance with the Declaration of Helsinki and Ethical Guidelines for Clinical Research (Ministry of Health, Labour, and Welfare, Japan). The trial was registered at University Hospital Medical Information Network-Clinical Trial Registry (UMIN-CTR) (http://www.umin.ac.jp/ctr/index-j.htm), identification number (UMIN000000486).

Patient registration and data collection were managed by the Makimoto-han datacenter. The quality of the data was ensured by a careful review performed by the data center staff and the coordinating investigator of this study (MI). All data were fixed on November 13, 2009, and all analyses in this study were performed by statisticians (NY and TS).

Results

Patient characteristics

Sixty-one patients were enrolled in this trial between July 2006 and November 2007 at 20 institutions in Japan (see the Appendix in Supplementary Material). However, 1 patient was excluded before the start of protocol treatment because distant lymph node metastases were detected during a CT examination for radiation field planning; this patient received systemic chemotherapy with gemcitabine alone. Table 1 shows the characteristics of the 60 FAS patients.

Table 1 Patient characteristics (n=60)

Characteristics	No. of patients	Value(s)	% of patients
Age (y)			
Median		64	
Range		31-80	
Sex			
Male	35		58
Female	25		42
Eastern Cooperative Oncology Group performance status			
0	34		57
1	26		43
Biliary drainage			
Present	16		27
Pathology			
Adenocarcinoma	59		98
Adenosquamous carcinoma	1		2
Tumor location			
Head	33		55
Body or tail	27		45
Maximum tumor size, cm			
Median		3.6	
Range		2.0-6.5	
Regional lymph node swelling			
N0	44		73
N1	16		27
CA19-9 (U/ml)			
Median		304	
Range		0-4400	
Planning target volume (cm^3)			
Median		240	
Range		102-442	

Abbreviation: CA19-9 = carbohydrate antigen 19-9.

Fifty-three patients (88%) completed S-1 therapy and radiation therapy but the remaining 7 patients (12%) discontinued S-1 and radiation therapy. Reasons for treatment discontinuation were disease progression (2 patients), duodenal and bile duct perforation (1 patient), acute myocardial infarction (1 patient), treatment interruption for >15 days because of cholangitis (1 patient), severe confusion (1 patient), and patient refusal to continue treatment because of grade 3 nausea and vomiting (1 patient). The treatment delay during chemoradiation therapy was observed in 20 patients (33%), and the median delay was 3 days (range, 1-17 days). Compliance with S-1 therapy was high, with a rate of 99% (1170 of 1176 doses). Of the 53 patients who completed chemoradiation therapy 47 (89%) patients received maintenance S-1 chemotherapy, but 6 patients did not for the following reasons: disease progression (3 patients); sudden death because of septic shock of unknown origin occurring 40 days after the completion of S-1 and radiation therapy (1 patient); and patient refusal to continue treatment because of grade 2 nausea and grade 2 diarrhea (1 patient) or grade 3 appetite loss and grade 2 fatigue (1 patient). The median number of S-1 maintenance chemotherapy courses was 4 (range, 1 to ≥19). At the time of the final analysis, S-1 maintenance chemotherapy had been terminated in 46 (98%) of 47 patients because of disease progression (29 patients, 63%), adverse events (12 patients, 26%), patient refusal (2 patients, 4%), or other reasons (3 patients, 7%). Treatment delay during the first and second courses of maintenance S-1 therapy was observed in 9 patients (19%) and 7 patients (18%), respectively. The rate of compliance with S-1 chemotherapy was 91% (2503 of 2744 doses) in the first course and 98% (2149 of 2184 doses) in the second course. After the completion of protocol treatment, 53 patients (88%) received subsequent therapy including gemcitabine (47 patients), S-1 (11 patients), radiation therapy for bone metastases (2 patients), and other treatments (4 patients).

Toxicity

The toxicities of S-1 and radiation therapy observed in the 60 FAS patients are listed in Table 2. Grade 3 leukocytopenia, neutropenia, and anemia occurred in 6 (10%), 3 (5%), and 2 (3%) patients, respectively; no grade 4 hematological toxicity was seen. The most common and troublesome non-hematological toxicities for patients undergoing chemoradiation therapy were usually gastrointestinal toxicities, including anorexia, nausea, and vomiting. However, grade 3 or higher cases of these toxicities were observed only in 4 (7%), 3 (5%), and 2 (3%) patients, respectively, and the toxicities were generally mild and manageable. One treatment-related death arising from perforation of the duodenum and biliary tract occurred during chemoradiation therapy.

Toxicities occurring during S-1 maintenance chemotherapy were also mild and transient (Table 3). Grade 4 leukocytopenia was the only hematological toxicity, and it was observed in only 1 patient (2%); the incidence of grade 3 or higher gastrointestinal toxicities was <6%. In addition, no serious adverse events occurred during S-1 maintenance chemotherapy. No late toxicities that could be associated with S-1 and radiation therapy were reported.

Efficacy

The response evaluation included all 60 FAS patients, but tumor response was not evaluable in 1 patient in whom contrast-enhanced CT examination could not be performed due to deterioration of her general condition following duodenal perforation.

Table 2 Toxicity during S-1 and concurrent radiation therapy (n=60)

Toxicity	No. of patients (%)*			
	Grade 1	Grade 2	Grade 3	Grade 4
Hematological				
Leukocytes	15 (25)	28 (47)	6 (10)	0 (0)
Neutrophils	9 (15)	15 (25)	3 (5)	0 (0)
Hemoglobin	16 (27)	13 (22)	2 (3)	0 (0)
Platelets	24 (40)	3 (5)	0 (0)	0 (0)
Non hematological				
Rash	2 (3)	0 (0)	0 (0)	0 (0)
Pigmentation	6 (10)	0 (0)	0 (0)	0 (0)
Hand-foot syndrome	1 (2)	0 (0)	0 (0)	0 (0)
Gastric ulcer/gastritis	0 (0)	1 (2)	1 (2)	0 (0)
Abdominal pain	0 (0)	0 (0)	1 (2)	0 (0)
Bilirubin	4 (7)	1 (2)	1 (2)	0 (0)
Aspartate aminotransferase	11 (18)	3 (5)	0 (0)	0 (0)
Alanine aminotransferase	10 (17)	5 (8)	0 (0)	0 (0)
Alkaline phosphatase	4 (7)	0 (0)	0 (0)	0 (0)
Hypoalbuminemia	15 (25)	7 (12)	0 (0)	-
Amylase	0 (0)	1 (2)	0 (0)	-
Creatinine	0 (0)	0 (0)	0 (0)	0 (0)
Hyperglycemia	2 (3)	4 (7)	0 (0)	0 (0)
Cholangitis	0 (0)	1 (2)	0 (0)	0 (0)

* Grading followed Common Terminology Criteria for Adverse Events version 3.0.

Tumor response was evaluated based on the best response as of 24 weeks after S-1 and radiation therapy were started. Overall, a partial response was seen in 16 patients for an overall response rate of 27% (95% confidence interval [CI], 16%-40%). The median survival in patients with partial response was 19.4 months (range, 9.8-32.6 months; 95% CI, 13.9-25.1 months), with a median duration of response of 7.3 months (range, 5.5-10.1 months). Forty patients (67%) showed stable disease, and 3 patients (5%) had progressive disease. Additionally, tumor response was evaluated for all periods because tumor shrinkage was obtained in some patients after 24 weeks. Of the 40 patients who were judged to have stable disease on the response evaluation at 24 weeks, an additional 6 patients were judged to have a partial response by the central independent reviewers. The median time to partial response was 4.7 months (range, 1.4-16.8 months) after chemoradiation therapy commenced. Therefore, the response rate for all periods was 37% (95% CI, 25%-50%). Of the 42 patients with a pretreatment serum CA19-9 level ≥100 U/ml, 34 (81%) patients had a >50% decrease compared to the pretreatment level. During this protocol treatment, 2 patients underwent surgical resection because tumor shrinkage occurred and their tumors became resectable.

Fifty-four of the 60 patients had disease progression at the time of the analysis. The median progression-free survival time and the 6-month and 1-year progression-free survival proportions for all patients were 9.7 months (95% CI, 6.9-11.6 months), 68%, and 32%, respectively (Fig.). The pattern of disease progression was distant metastases in 26 patients (46%), locoregional recurrence in 16 patients (27%), distant metastases and locoregional recurrence in 3 patients (5%), and deterioration of general condition in 9 patients (15%). At the time of analysis, 49 patients had died, and the median follow-up period was 16.3 months (range, 3.0-34.0 months). The median survival time and the 1-year and 2-year survival proportions for the 60 patients were 16.2 months (95% CI, 13.5-21.3 months), 72% (95% CI, 59%-82%), and 26%, respectively (Fig.).

Table 3 Toxicity during S-1 maintenance therapy (n=47)

Toxicity	No. of patients (%)*			
	Grade 1	Grade 2	Grade 3	Grade 4
Hematological				
Leukocytes	4 (9)	27 (57)	4 (9)	1 (2)
Neutrophils	5 (11)	19 (40)	6 (13)	0 (0)
Hemoglobin	8 (17)	18 (38)	3 (6)	0 (0)
Platelets	8 (17)	2 (4)	1 (2)	0 (0)
Non hematological				
Malaise	13 (27)	8 (17)	2 (4)	0 (0)
Anorexia	15 (32)	11 (23)	3 (6)	0 (0)
Nausea	7 (15)	4 (9)	1 (2)	0 (0)
Vomiting	4 (9)	1 (2)	0 (0)	0 (0)
Diarrhea	3 (6)	3 (6)	0 (0)	0 (0)
Stomatitis	4 (9)	0 (0)	0 (0)	0 (0)
Alopecia	1 (2)	0 (0)	-	-
Rash	2 (4)	1 (2)	0 (0)	0 (0)
Pigmentation	11 (23)	1 (2)	0 (0)	0 (0)
Hand-foot syndrome	1 (2)	0 (0)	0 (0)	0 (0)
Duodenal ulcer	0 (0)	1 (2)	0 (0)	0 (0)
Taste alteration	1 (2)	2 (4)	-	-
Bilirubin	7 (15)	5 (11)	0 (0)	0 (0)
Aspartate aminotransferase	8 (17)	3 (6)	1 (2)	0 (0)
Alanine aminotransferase	5 (11)	2 (4)	0 (0)	0 (0)
Alkaline phosphatase	1 (2)	0 (0)	0 (0)	0 (0)
Hypoalbuminemia	10 (21)	5 (11)	0 (0)	-
Amylase	0 (0)	1 (2)	0 (0)	-
Creatinine	3 (6)	0 (0)	0 (0)	0 (0)
Hyperglycemia	2 (4)	4 (9)	0 (0)	0 (0)

* Grading followed Common Terminology Criteria for Adverse Events version 3.0.



Fig. Overall survival and progression-free survival curves of the 60 locally advanced PC patients treated with S-1 with concurrent radiation therapy. Censored cases are shown by tick marks.

Radiation therapy quality assurance

Radiation therapy quality assurance was reviewed centrally by an independent radiation committee for all 60 FAS patients. DA was observed for 2 parameters in 4 patients (relationship between GTV and radiation field, 2 patients; isodose distribution, 2 patients), but no instances of VU were seen in this study. Therefore, PPoverall, DAoverall, and VUoverall were assessed in 56 (93%) patients, 4 (7%) patients, and 0 (0%) patients, respectively.

Discussion

The combination of radiation therapy and 5-FU chemotherapy has been acknowledged as a standard therapy for locally advanced PC (1-4). However, optimal chemotherapeutic regimens continue to be pursued, as the survival benefit remains modest. S-1 is the first single anticancer agent to be judged non-inferior to gemcitabine in a large-scale randomized phase III trial for advanced PC (10), and it is expected to become a first-line treatment for patients with advanced PC, at least in Asian countries. In addition, it has been shown that combined S-1 and radiation therapy has a synergistic effect against 5-FU-resistant cancer xenografts; thus, S-1 may also have a radiosensitizing effect (11). With S-1 and standard-dose radiation therapy (50.4 Gy/28 fractions), the full dose (80 mg/m^2) of S-1 can be given on the day of irradiation (12) with a reduced risk of distant metastases. Therefore, S-1 may act not only against systemic tumor spread but also a as a potent radiosensitizer to enhance local control. Furthermore, the fact that S-1 can be given orally is an additional benefit over 5-FU infusion.

In the present multicenter trial, the 24-week tumor response rate was 27%, although the overall tumor response rate for the complete period was 37%; in fact, tumor resection was possible in 2 patients after treatment. Thus, excellent tumor shrinkage appears to be an additional benefit of this treatment. Furthermore, other outcomes, including the serum CA19-9 level response (81%), progression-free survival (median, 9.7 months), and overall survival (median, 16.2 months), showed excellent results. As the subsequent therapy, most patients (78%) received gemcitabine, as it might lead to favorable overall survival. However, the outcome of S-1 and concurrent radiation therapy has been reported by other groups (14-16), which were single institutional studies with small numbers of enrolled patients and had slight differences in S-1 administration (Table 4). Similar results were obtained, although such nonrandomized data must be interpreted with caution. Given the recent reports of chemoradiation therapy (4-8, 17, 18), S-1 with concurrent radiation therapy appears to have a favorable treatment efficacy for locally advanced PC, and its survival time will approach that of resected PC patients.

During chemoradiation therapy the major troublesome adverse events were gastrointestinal toxicities (anorexia, nausea, and vomiting), which required intravenous fluid infusion and, sometimes, the termination of chemoradiation therapy (4). One approach to reducing these toxicities that has recently come to be used in chemoradiation therapy using conventional photons for the treatment of PC (4, 6), is a limited radiation field, with a PTV including gross tumor volume alone, without prophylactic nodal irradiation; this minimizes the irradiation of normal tissue and was adopted in the present study. Grade 3 or higher of the above-mentioned toxicities were observed in less than 7% of the patients, and the gastrointestinal toxicities were very mild and easily managed. Other grade 3 or higher non hematological and hematological toxicities of S-1 and concurrent radiation therapy were observed in only 10% or less of the patients and were mild, although there was one treatment-related death due to a perforated duodenum. The toxicities associated with maintenance S-1 therapy were also mild, and this regimen was considered to be well tolerated.

Regarding the results of the radiation therapy quality assurance evaluations performed in this study, 93% of the treatments were assessed as PPoverall; this result is excellent compared with that of a previous trial (5). This result was achieved thanks to the efforts made by the radiation oncologists. The radiation technique that was used in this study was thoroughly explained to all of the radiation oncologists at each institution before patient registration, and the radiation therapy records of the enrolled patients were reviewed by the radiation committee. Results of the review were returned to the radiation oncologists at each institution if any problem with the radiation technique was noted. Therefore, a high quality of radiation therapy was maintained in this study.

There continues to be debate about the role of chemoradiation therapy for patients with locally advanced PC. Prior to the 1990s, it was shown that concurrent external-beam radiation therapy and 5-FU chemotherapy offers a survival benefit over radiation therapy (1, 2) or chemotherapy alone (3). Since the introduction of gemcitabine, which is acknowledged as the first-line therapy for advanced PC, 2 randomized controlled trials comparing chemoradiation therapy with gemcitabine alone have been reported:

Table 4 Results of phase II trials of S-1 and radiation therapy for locally advanced pancreatic cancer

Study (ref.)	Y	Chemotherapy	Radiation therapy	No. of patients	Response rate	Median survival time (mo)	1-y survival rate (%)	Median progression-free survival time (mo)	Maintenance chemotherapy
Kim et al (20)	2008	S-1, 80 mg/m^2, days 1-14 and 22-35	50.4 Gy/28 fractions	25	24%	12.9	43%	6.5	Gemcitabine-based regimen
Sudo et al (15)	2011	S-1, 80 mg/m^2, days 1-14 and 22-35	50.4 Gy/28 fractions	34	41%	16.8	70.6%	8.7	S-1
Shinchi et al (16)	2011	S-1, 80 mg/m^2, days 1-21	50 Gy/40 fractions	50	30%	14.3	62%	6.7	S-1
Current study		S-1, 80 mg/m^2, on the day of irradiation	50.4 Gy/28 fractions	60	27%	16.2	72%	9.7	S-1

a French group reported an inferior outcome with radiation therapy plus 5-FU and cisplatin to chemotherapy with gemcitabine alone (17); and the ECOG study demonstrated that radiation therapy plus gemcitabine had a superior survival outcome compared with gemcitabine alone (18). Thus, these 2 recent randomized controlled trials comparing chemoradiation therapy with gemcitabine alone demonstrated opposite survival results, although both trials were terminated halfway through because of poor patient accrual. In addition, gemcitabine monotherapy for locally advanced PC has been reported to have a favorable efficacy (median survival, 15 months) according to our Japanese group (19), although the time to treatment failure (median, 6.0 months) was not optimal. Thus, in patients with locally advanced PC, it is not clear whether chemoradiation therapy or chemotherapy alone has a better outcome, and there is a need for a prospective, randomized, controlled study comparing chemoradiation therapy with chemotherapy in such patients. Recently, induction chemotherapy followed by chemoradiation therapy has been reported (20). The role of induction chemotherapy is to prevent distant metastases and to define a subset of patients who are likely to benefit from chemoradiation therapy excluding patients with chemoresistant and rapidly progressive disease. Further clinical trials are needed to elucidate the usefulness of this therapeutic strategy.

Conclusions

S-1 therapy with concurrent radiation therapy had very favorable activity, with mild toxicity in patients with locally advanced PC, and the survival time of such patients is expected to approach that of resected PC patients. This regimen appears to be a good platform for incorporation of biologic agents, and the present results should be confirmed in a prospective, randomized, controlled study to elucidate whether chemoradiation therapy or chemotherapy alone results in a better treatment outcome.

References

1. Moertel CG, Childs DS, Reitemeier RJ, et al. Combined 5-fluorourail and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. *Lancet* 1969;2:865-867.
2. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. *Cancer* 1981; 48:1705-1710.
3. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. *J Natl Cancer Inst* 1988;80:751-755.
4. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. *J Clin Oncol* 2009;27:2269-2277.
5. Mamon HJ, Niedzwiecki D, Hollis D, et al., for the Cancer and Leukemia Group B. A phase 2 trial of gemcitabine, 5-florouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003. *Cancer* 2011;117:2620-2628.
6. Crane CH, Winter K, Regine WF, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. *J Clin Oncol* 2009; 27:4096-4102.
7. Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2010;78:735-742.
8. Schellenberg D, Kim J, Christman-Skieller C, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2011;81:181-188.
9. Okusaka T, Funakoshi A, Furuse J, et al. A late phase II study of S-1 for metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 2008; 61:615-621.
10. Ioka T, Ikeda M, Ohkawa S, et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study [Abstract 4007]. *J Clin Oncol* 2011;29(suppl 4058).
11. Fukushima M, Sakamoto K, Sakata M, et al. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. *Oncol Rep* 2010;24:1307-1313.
12. Ikeda M, Okusaka T, Ito Y, et al. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. *Br J Cancer* 2007;96:1650-1655.
13. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. *Lancet Oncol* 2008;9:132-138.
14. Kim HM, Bang S, Park JY, et al. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. *Cancer Chemother Pharmacol* 2009;63:535-541.
15. Sudo K, Yamaguchi T, Ishihara T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2011;80:119-125.
16. Shinchi H, Maemura K, Mataki Y, et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. *J Hepatobiliary Pancreat Sci* 2012;19:152-158.
17. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. *Ann Oncol* 2008;19:1592-1599.
18. Loehrer PJ Sr., Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial. *J Clin Oncol* 2011;29:4105-4112.
19. Ishii H, Furuse J, Boku N, et al. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. *Jpn J Clin Oncol* 2010;40:573-579.
20. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. *Cancer* 2007;110:47-55.

Pancreatology 12 (2012) 428–433

Contents lists available at SciVerse ScienceDirect

Pancreatology

journal homepage: www.elsevier.com/locate/pan

Original article

Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy

Tomoko Katsui Taniyama [a], Chigusa Morizane [a,*], Kohei Nakachi [b], Satoshi Nara [c], Hideki Ueno [a], Shunsuke Kondo [a], Tomoo Kosuge [c], Kazuaki Shimada [c], Minoru Esaki [c], Masafumi Ikeda [b], Shuichi Mitsunaga [b], Taira Kinoshita [d], Masaru Konishi [d], Shinichiro Takahashi [d], Takuji Okusaka [a]

[a] Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
[b] Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
[c] Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan
[d] Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital East, Chiba, Japan

ARTICLE INFO

Article history:
Received 22 May 2012
Received in revised form
16 July 2012
Accepted 17 July 2012

Keywords:
Adjuvant chemotherapy
Chemotherapy
Gemcitabine
Recurrent pancreatic cancer
S-1

ABSTRACT

Objectives: A global consensus on how to treat recurrent pancreatic cancer after adjuvant chemotherapy with gemcitabine (ADJ-GEM) does not exist.
Methods: We retrospectively reviewed the clinical data of 41 patients with recurrences who were subsequently treated with chemotherapy.
Results: The patients were divided into two groups according to the time until recurrence after the completion of ADJ-GEM (ADJ-Rec): patients with an ADJ-Rec < 6 months ($n = 25$) and those with an ADJ-Rec ≥ 6 months ($n = 16$). The disease control rate, the progression-free survival after treatment for recurrence and the overall survival after recurrence for these two groups were 68 and 94% ($P = 0.066$), 5.5 and 8.2 months ($P = 0.186$), and 13.7 and 19.8 months ($P = 0.009$), respectively. Furthermore, we divided the patients with an ADJ-Rec < 6 months into two groups: patients treated with gemcitabine ($n = 6$) and those treated with alternative regimens including fluoropyrimidine-containing regimens ($n = 19$) for recurrent disease. Patients treated with the alternative regimens had a better outcome than those treated with gemcitabine.
Conclusions: Fluoropyrimidine-containing regimens may be a reasonable strategy for recurrent disease after ADJ-GEM and an ADJ-Rec < 6 months.

1. Introduction

Pancreatic cancer patients have an extremely poor prognosis. Although surgical resection is the only curative treatment, only 15%–20% of patients are candidates for resection. Even if a curative resection is performed, the 5-year-survival rate is only 10%–25%, and the median survival period is 11–20 months [1,2].

Various adjuvant chemotherapy or chemoradiotherapy regimens after surgical resection have been evaluated [2–6]. Recently, The Charite' Onkologie (CONKO)-001 trial was designed to determine the benefits of gemcitabine for patients with resected pancreatic cancer. Adjuvant chemotherapy with gemcitabine (ADJ-GEM) significantly improved the disease-free survival period, compared with surgery alone, in patients with resected pancreatic cancer. Although no significant difference in overall survival was seen at the time of publication, analysis after a longer follow-up period demonstrated a survival advantage for gemcitabine over observation-only (median progression-free survival, 22.8 months for ADJ-GEM vs. 20.2 months for observation-only; $P = 0.005$). At approximately the same time as the CONKO-001 trial, the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP) conducted a randomized clinical trial evaluating adjuvant gemcitabine. Although no significant difference in overall survival was seen, the patients in the gemcitabine arm demonstrated a significantly longer disease-free survival period than the patients in the observation-only arm. These results were similar to those of the CONKO-001 trial and supported the concept that adjuvant chemotherapy using gemcitabine was effective in an Asian

* Corresponding author. Tel.: +81 3 3542 2511; fax: +81 3 3542 3815.
E-mail address: cmorizan@ncc.go.jp (C. Morizane).

1424-3903/$ – see front matter
http://dx.doi.org/10.1016/j.pan.2012.07.016

population [2,5]. Therefore, adjuvant therapy using gemcitabine for resected pancreatic cancer is now firmly established as a therapy that offers a modest but real improvement in overall survival [5,7].

In approximately 50% of patients, recurrent disease was reportedly seen within a year, even after receiving ADJ-GEM [5], and no global consensus exists regarding treatment strategies for recurrent disease after ADJ-GEM. If the length of time from the completion of adjuvant therapy until the detection of recurrence is less than 6 months, the NCCN guidelines recommend alternative chemotherapy using a fluoropyrimidine-based chemotherapy regimen. When this period is 6 months or greater, they recommend an alternative regimen or the same regimen as the previous therapy [8]. However, these recommendations have not been substantiated by actual clinical data.

In Japan, the oral fluoropyrimidine derivative S-1 is often used as an alternative regimen for gemcitabine-refractory cases. S-1 showed a non-inferiority to gemcitabine in terms of overall survival in a phase III trial and is considered an alternative to gemcitabine for chemonaïve patients with advanced pancreatic cancer [9]. Additionally, in gemcitabine-refractory metastatic cases, a recent phase II study of S-1 yielded results that demonstrated preferable activity, including a response rate of 9.5%–15% and a median overall survival time of 4.5–6.3 months [10,11]. Therefore, S-1 is widely used for the treatment of advanced pancreatic cancer in first-line and second-line settings in Japan.

We studied the current status of treatments for recurrent pancreatic cancer after curative resection followed by ADJ-GEM. The objective of this study was to examine the adequacy of the

Table 1
Patient characteristics at resection ($n = 41$).

		n (%)			
	Variables	All patients $n = 41$	ADJ-Rec < 6 months $n = 25$	ADJ-Rec ≥ 6 months $n = 16$	*P* value
Age (years)	Median (range)	65 (38–78)	64 (38–78)	65 (50–77)	0.96
Gender	Male	27 (66)	16 (64)	11 (69)	1.00
	Female	14 (34)	9 (36)	5 (31)	
PS[a] at recurrence	0	30 (73)	20 (80)	10 (63)	0.34
	1	5 (12)	3 (12)	2 (12)	
	Unknown	6 (15)	2 (8)	4 (25)	
Primary site	Head	26 (63)	17 (68)	9 (56)	0.51
	Body or -tail	15 (37)	8 (32)	7 (44)	
Type of Resection	PD[b]	26 (64)	17 (68)	9 (56)	0.66
	DP[c]	12 (29)	6 (24)	6 (38)	
	TP[d]	3 (7)	2 (8)	1 (6)	
Resection status	R0	36 (88)	22 (88)	14 (88)	1.00
	R1	5 (12)	3 (12)	2 (12)	
Histology	Adenocarcinoma	39 (95)	23 (92)	16 (100)	0.51
	Adenosquamous carcinoma	2 (5)	2 (8)	0 (0)	
Stage[e] at resection	IIA	5 (12)	0 (0)	5 (31)	0.006
	IIB	36 (88)	25 (100)	11 (69)	
CEA[f] (ng/mL)	Median (range)	2.7 (0.7–51.8)	2.7 (0.7–21.0)	2.4 (1.2–51.8)	0.98
CA19-9[g] (U/mL)	Median (range)	202 (0.5–6450)	212 (0.5–6450)	138 (17–3203)	0.56
Histological grade	Well	5 (12)	3 (12)	2 (12.5)	0.83
	Moderately	28 (71)	17 (68)	12 (75)	
	Poorly	7 (17)	5 (20)	2 (12.5)	
Lymph node ratio[h]	0	5 (12)	0 (0)	5 (31)	0.008
	0.1–0.199	23 (56)	14 (56)	9 (57)	
	0.2–0.299	8 (20)	7 (28)	1 (6)	
	0.3–	4 (10)	4 (16)	0 (0)	
	Unknown	1 (2)	0 (0)	1 (6)	
Recurrent pattern[i]	Locoregional	21 (51)	10 (40)	11 (69)	0.15
	Liver	18 (44)	14 (56)	4 (25)	
	Peritoneum	4 (10)	4 (16)	0 (0)	
	Lungs	11 (27)	7 (28)	4 (25)	
	Bones	1 (2)	1 (4)	0 (0)	
Cycles of ADJ-GEM	Median (range)	6 (3–9)	6 (3–6)	6 (3–9)	0.88
ADJ-Rec[j] (months)	Median (range)	3.7(0.1–36.1)	1.3 (0.1–4.9)	11.5 (6.3–36.1)	
Chemotherapy[k]	GEM	21 (51)	6 (24)	15 (94)	0.00
	Alternatives[l]	20 (49)	19 (76)	1 (6)	
	(S1)	17 (41)	17 (68)	1 (6)	
	(GEM + S1)	1 (2)	0 (0)	0 (0)	
	(S1 + Radiation)	1 (2)	1 (4)	0 (0)	
	(S1 + oxaliplatin)	1 (2)	1 (4)	0 (0)	

[a] PS, performance status.
[b] PD, pancreaticoduodenectomy.
[c] DP, distal pancreatectomy.
[d] TP, total pancreatectomy.
[e] Stage, UICC 7th.
[f] CEA, carcinoembryonic antigen at resection.
[g] CA-19-9, carbohydrate antigen 19-9 at resection.
[h] Lymph node ratio, number of metastatic lymph nodes divided by number of examined nodes.
[i] Recurrent pattern, numbers of locoregional, extra-pancreatic, and combined recurrences were 11, 20, and 10 patients.
[j] ADJ-Rec, period between the last date of ADJ-GEM and recurrence.
[k] Chemotherapy, chemotherapy for recurrent disease after adjuvant chemotherapy.
[l] Alternatives, all alternative regimens consisted of fluoropyrimidine-containing regimens.

NCCN guidelines for recurrent pancreatic cancer after adjuvant chemotherapy, which recommend that the treatment options should be determined by the period between the last date of ADJ-GEM and recurrence (ADJ-Rec), with a threshold of 6 months.

2. Patients and methods

2.1. Patients

A retrospective review was conducted for 113 pancreatic cancer patients who underwent curative resection followed by ADJ-GEM at the National Cancer Center Hospital (NCCH) and NCCH East in Japan between April 2002 and October 2010. Forty-two patients with no recurrence after ADJ-GEM, 10 patients with withdrawal from ADJ-GEM within 2 cycles, 6 patients with recurrence during ADJ-GEM, and 14 patients who changed hospitals after recurrence were excluded. We finally retrieved the clinical data of 41 patients with recurrences who were subsequently treated with chemotherapy at our hospitals.

2.2. Treatment

After resection, we started ADJ-GEM within 10 weeks. An initial gemcitabine dose of 1000 mg/m^2 was administrated intravenously for 30 min on days 1, 8 and 15 every 4 weeks for 3 to 6 cycles, in principle. A computed tomography examination was performed every 3–6 months. Once evidence of recurrence was revealed, treatment for recurrent disease was initiated.

2.3. Data collection and evaluation of tumor response

The following data were collected from the medical records: patient characteristics at resection, the resection status, the ADJ-Rec, the treatment regimen, and the outcome of treatment after the recurrence. We also compared the treatment outcomes according to the length of the ADJ-Rec and the treatment regimens. Tumor responses were evaluated according to the RECIST criteria, Ver.1.1. We evaluated the best overall response and the disease control rate (DCR). The DCR was defined as the rate of complete response + partial response + stable disease. When the disease status was stably maintained for more than 8 weeks, the patient was considered to have stable disease.

2.4. Statistical analysis

The Fisher exact test was used to assess the hypothesis of independence between categorical variables. For quantitative data such as age and the carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels, we used the Mann–Whiney test. ADJ-Rec was defined as the period between the last date of the administration of ADJ-GEM and the date on which local or distant recurrence was noted. The date of recurrence was defined as the date of documentation of recurrent disease using diagnostic imaging techniques. Progression-free survival (PFS) was defined as the period between the start of treatment for recurrent disease and the date of progression, the last follow-up visit, or death from any cause. Overall survival after recurrence (r-OS) was defined as the period between the start of treatment for recurrent disease and death from any cause or the last follow-up. Patients who were lost to follow-up were treated as censored cases. Survival curves were estimated using the Kaplan–Meier method, and the significances were evaluated using a log-rank test. All the analyses were performed using Stata/SE, Version 11.1 (StataCorp, USA).

3. Results

3.1. Patient characteristics

The characteristics at resection of the 41 eligible patients are listed in Table 1. R0 resection (complete resection with no microscopic residual tumor) was performed in 36 patients (88%). Concerning the pathological stage, 5 (12%) of the patients had stage IIA disease and 36 (88%) had stage IIB. The sites of recurrence were locoregional (21 patients), the liver (18 patients), and the lung (11 patients). Patients with an ADJ-Rec $\geq$ 6 months (16 patients) had a significantly better status than patients with an ADJ-Rec $<$ 6 months (25 patients) with regard to disease stage ($P = 0.006$) and the lymph node ratio (the number of metastatic lymph nodes divided by the number of examined nodes) ($P = 0.0075$). As for the treatments for recurrent disease, 21 patients were treated with gemcitabine monotherapy and 20 patients were treated with alternative regimens. All the alternative regimens were fluoropyrimidine-containing regimens (17 patients received S-1 and 1 patient each received GEM + S-1, S-1 + radiation, and S-1 + oxaliplatin). The treatment strategy after recurrence depended on each oncologist's plan, without a unified policy. Among the 25 patients with an ADJ-Rec $<$ 6 months, 6 were treated with gemcitabine monotherapy and 19 were treated with alternative regimens. Among the 16 patients with an ADJ-Rec $\geq$ 6 months, 15 were treated with gemcitabine monotherapy and 1 was treated with an alternative regimen.

3.2. Treatment efficacy and survival analysis of treatments for recurrence

Overall, 2 of the 41 patients responded to the treatments for recurrent disease (4.9%; 2 partial responses; 95% confidence interval (95% CI), 0.60%–16.53%). The DCR was 78% (32 of the 41 patients; 95% CI, 62.39%–89.44%). The median PFS and median r-OS were 5.5 months (95% CI, 3.7–8.1 months) and 18.3 months (95% CI, 13–19.8 months), respectively (Fig. 1).

We divided the patients into two groups according to the length of the ADJ-Rec: patients with an ADJ-Rec $<$ 6 months ($n = 25$), and patients with an ADJ-Rec $\geq$ 6 months ($n = 16$). The DCRs were 68% and 94% ($P = 0.066$), and the median PFS periods were 5.5 and 8.2 months ($P = 0.186$; Fig. 2A), respectively. The median r-OS of the patients with an ADJ-Rec $<$ 6 months was significantly shorter than



Fig. 1. Progression-free survival (PFS) and overall survival after recurrence (r-OS) in all patients ($n = 41$). The median PFS and r-OS were 5.5 and 18.3 months, respectively.



Fig. 2. Progression-free survival (PFS) and overall survival after recurrence (r-OS) according to the length of the ADJ-Rec: patients with an ADJ-Rec < 6 months ($n = 25$), and patients with an ADJ-Rec ≥ 6 months ($n = 16$). (A) The median PFS for each group was 5.5 and 8.2 months ($P = 0.186$), respectively. (B) The median r-OS was 13.7 and 19.8 months ($P = 0.009$), respectively.

that of the patients with an ADJ-Rec ≥ 6 months (13.7 and 19.8 months, $P = 0.009$; Fig. 2B).

Additionally, we divided the patients with an ADJ-Rec < 6 months into two groups according to the treatment regimens for recurrent disease: patients treated with gemcitabine ($n = 6$) and patients treated with alternative regimens ($n = 19$). The outcomes are shown in Table 2 and Fig. 3. For the patients treated with gemcitabine and those treated with alternative regimens, the DCR, median PFS and median r-OS were 67% and 68% ($P = 0.651$), 2.9 and 6.5 months ($P = 0.065$; Fig. 3A), and 7.7 and 13.0 months ($P = 0.242$; Fig. 3B), respectively.

4. Discussion

In this study, at first we examined the current status of the treatment strategy for pancreatic cancer patients with recurrence after adjuvant chemotherapy. Most patients with ADJ-Rec ≥ 6 months were placed on gemcitabine. Even for patients with an ADJ-Rec < 6 months, gemcitabine was resumed in 24% of these patients. Generally, patients who relapse within a short period after receiving adjuvant chemotherapy should be considered as being resistant to those drugs. The NCCN guidelines also recommend that the options for recurrent disease after adjuvant therapy should be assessed according to the ADJ-Rec. However, these guidelines are only the recommendation of the panel, and these strategies have not yet been substantiated by actual clinical data. In the case of ovarian cancer, a consensus based on actual clinical data exists with regard to the treatment strategy for relapsed disease. Patients who have relapsed within an interval of less than 6 months since the previous paclitaxel-plus-platinum chemotherapy should be considered as platinum resistant [12,13]. However, the chemosensitivity and the key drugs are quite different between pancreatic cancer and ovarian cancer. Therefore, actual clinical data for pancreatic cancer is needed.

The outcome of patients with a short ADJ-Rec was worse than that of the patients with a long ADJ-Rec. This finding suggests that patients with a long ADJ-Rec may owe their period of prolonged sensitivity to the adjuvant gemcitabine treatment, slow tumor growth, and a smaller quantity of residual tumor. Concerning advanced pancreatic cancer, similar findings have been reported in a previous study, which indicated that the progression-free survival period after first-line chemotherapy was an independent prognostic factor [14]. Additionally, patients with pathological stage IIA or a lymph node ratio of 0 had a long ADJ-Rec in the present study, possibly influencing the outcome. However, our results should be interpreted with caution because biases introduced by the different selection of treatment regimens between the two groups may exist.

Among the patients with an ADJ-Rec ≥ 6 months, we were unable to compare the treatment outcome according to regimens, since most of them (15 out of 16) received gemcitabine monotherapy and seldom received alternative options such a fluoropyrimidine-based regimens. In the present study, the patients treated with gemcitabine had a better DCR, PFS and r-OS than the metastatic or recurrent pancreatic cancer patients treated with gemcitabine in past studies [15,16]. Even after considering the possibility that an ADJ-Rec ≥ 6 months may be a good prognostic factor, these preferable outcomes suggest the appropriateness of a re-challenge with gemcitabine.

Among the patients with an ADJ-Rec < 6 months, patients receiving alternative regimens tended to have a better DCR, PFS,

Table 2
Outcomes of patients according to ADJ-Rec and treatment regimens.

	<6 months				≥6 months			
ADJ-Rec	All	GEM	Alternative	*P* value	All	GEM	Alternative	*P* value
n	25	6	19		16	15	1	
DCR (%)	68	67	68	1.00	94	93	(100)	1.00
95% CI	62.4–89.4	22.3–95.7	43.5–87.4		69.8–99.8	68.1–99.8	2.5–100	
Median PFS (m)	5.5	2.9	6.5	0.06	8.2	8.2	(12.2)	0.69
95% CI	2.6–6.6	1.5–	2.1–8.1		3.4–12.2	3.0–13.8		
Median r-OS(m)	13.7	7.7	13.0	0.24	19.8	20.9	(19.8)	0.67
95% CI	6.5–15.3	2.9–	6.5–		9.6–31.4	9.6–31.4		

ADJ-Rec, period between the last date of ADJ-GEM and recurrence; DCR, disease control rate; PFS, progression-free survival time; r-OS, survival time from recurrence; Alternative*, including S-1, GEM + S-1, S-1 + radiation, and S-1 + oxaliplatin.

and r-OS than those receiving gemcitabine monotherapy. Although the optimal ADJ-Rec threshold was not clarified, the present results support the recommendations of the NCCN guidelines, which recommend alternative regimens for patients with an ADJ-Rec < 6 months after previous treatment with gemcitabine. These findings suggest that a certain proportion of patients with a short ADJ-Rec may already have a gemcitabine-refractory status at the time of ADJ-GEM.

This study had some limitations. This study was a retrospective analysis with an insufficient sample size, and the treatment strategy after recurrence depended on each oncologist's plan, with no unified policy. Another limitation concerns the alternative treatment options after recurrence. The NCCN guidelines recommend alternative regimens as second-line therapies for metastatic disease. The recommended regimens consist of fluoropyrimidine-based therapies, such as 5-FU/leucovorin (LV)/oxaliplatin (Oxal) [17] or capecitabine/Oxal [18]. The CONKO-003 study revealed the survival advantage of 5-FU + LV + Oxal for gemcitabine-refractory pancreatic cancer. In Japan, these drugs have not yet been approved under the Japanese medical insurance system for the treatment of pancreatic cancer. S-1 monotherapy was mainly used as the alternative option in our study. Although S-1 demonstrated a non-inferiority to gemcitabine as a first-line treatment [8,9] and had a marginal activity as a second-line regimen for gemcitabine-refractory pancreatic cancer [10,11], it has not been accepted as a global standard therapy for gemcitabine-refractory pancreatic cancer.

In conclusion, patients with an ADJ-Rec ≥ 6 months had a relatively favorable outcome when treated with a gemcitabine rechallenge. Among the patients with an ADJ-Rec < 6 months, those patients receiving alternative regimens tended to have a better DCR, PFS, and r-OS, compared with those receiving gemcitabine. As a result, our results did not deny the appropriateness of strategies outline in the NCCN guidelines. A well-designed prospective study with a sufficient sample size is needed to identify the optimal regimen for the treatment of recurrent pancreatic cancer after postoperative adjuvant chemotherapy.



Fig. 3. Progression-free survival (PFS) and overall survival after recurrence (r-OS) according to treatments for recurrent disease in patients with an ADJ-Rec < 6 months: patients treated with gemcitabine ($n = 6$), and patients treated with alternative regimens ($n = 19$). (A) The median PFS for each group was 2.9 and 6.5 months ($P = 0.065$), respectively. (B) The median r-OS was 7.7 and 13.0 months ($P = 0.242$), respectively.

Grant support

None declared.

Conflict of interest

Takuji Okusaka had research findings and honoraria to disclose from Taiho pharmaceutical co. and Eli Lilly Japan.

Hideki Ueno had honoraria to disclose from Taiho pharmaceutical co. and Eli Lilly Japan, and had a consultation or advisory relationship to disclose from Taiho phatmaceutical co.

Tomoo Kosuge had honoraria to disclose from Taiho pharmaceutical co. and Eli Lilly Japan.

References

[1] Yeo Charles J, Cameron JL, Lillemoe KD. Pancreaticoduodenectomy for cancer of the head of the pancreas. Ann Surg 1995;221:721–33.
[2] Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267–77.
[3] Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.
[4] Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–10.
[5] Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer 2009;101:908–15.
[6] Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019–26.
[7] Riess H, Neuhaus P, Post S, Gellert K, Ridwelski K, Schramm H, et al. Conko-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). Ann Oncol 2008;19:45–6.
[8] NCCN clinical practice guidelines in oncology (NCCN guidelines®). Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp; December 7, 2011 [Accessed February 2012].
[9] Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Fukutomi A, Sugimori K, et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol 2011;29(suppl.). abstr 4007.
[10] Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009;63:313–9.
[11] Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011;67:249–54.
[12] Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 2002;3:537–45.
[13] Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099–106.
[14] Reni M, Berardi R, Mambrini A, Pasetto L, Cereda S, Ferrari VD, et al. A multicentre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2008;62:673–8.
[15] Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared

with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430–8.
[16] Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, et al. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology 2009;77: 217–23.
[17] Pelzer U, Stieler J, Schwaner I, Heil G, Seraphin J, Gorner M, et al. Results of the conko 003 trial. A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer. Onkologie 2008;31:98.
[18] Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:2046–52.

Original Paper

Neuro endocrinology

Neuroendocrinology 2012;96:324–332
DOI: 10.1159/000338794

Received: December 19, 2011
Accepted after revision: April 9, 2012
Published online: August 28, 2012

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

T. Terashima[a, f] C. Morizane[a] N. Hiraoka[e] H. Tsuda[b] T. Tamura[c] Y. Shimada[d]
S. Kaneko[f] R. Kushima[b] H. Ueno[a] S. Kondo[a] M. Ikeda[g] T. Okusaka[a]

[a]Hepatobiliary and Pancreatic Oncology Division, [b]Pathology Division, [c]Internal Medicine and Thoracic Oncology Division, and [d]Gastrointestinal Oncology Division, National Cancer Center Hospital, and [e]Pathology Division, National Cancer Center Research Institute, Tokyo, [f]Gastroenterology, Kanazawa University Hospital, Kanazawa, and [g]Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Key Words
Extrapulmonary neuroendocrine carcinoma · Small-cell lung carcinoma · Chemotherapy · Prognosis · Prognostic factor

Abstract
Background: The chemotherapy for small-cell lung carcinoma (SCLC) has been adopted for advanced extrapulmonary neuroendocrine carcinomas (EP-NECs). The aim of this study was to clarify the efficacy of standard SCLC regimens when used to treat EP-NECs and to compare the outcome with that for SCLC. ***Methods:*** We reviewed the medical records of 136 patients (41 with EP-NEC and 95 with SCLC) who were treated using a platinum-containing regimen for advanced disease between January 2000 and October 2008 at our hospital. ***Results:*** The primary site of the EP-NEC was the gastrointestinal tract in 18 patients (GI tract group); the liver, biliary tract or pancreas in 16 patients (HBP group), and other sites in 7 patients ('others' group). The response rate in the SCLC patients was 77.8%, and the response rate in the EP-NEC patients was 30.8% (37.5% in the GI tract group, 12.5% in the HBP group, and 57.1% in the 'others' group). The median survival time for the SCLC patients was 13.6 months, while that for the EP-NEC patients was 9.2 months (14.9 months in the GI tract group, 7.8 months in the HBP group, and 8.9 months in the 'others' group). A multivariate analysis demonstrated that a poor performance status, liver involvement, and the treatment regimen were independent unfavorable prognostic factors. ***Conclusion:*** The response rate and prognosis of the patients with advanced EP-NECs were worse than those of the patients with SCLC in this study. The Eastern Cooperative Oncology Group performance status, liver involvement, and treatment regimen had a larger impact on the prognosis than the primary tumor site, as demonstrated by multivariate analysis.

Introduction

Neuroendocrine neoplasms are defined as all neoplasms originating from endocrine glands, nerve elements, or from elements of the diffuse neuroendocrine system [1]. The World Health Organization (WHO) has proposed a grading system for neuroendocrine neo-

KARGER
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

0028–3835/12/0964–0324$38.00/0

Accessible online at:
www.karger.com/nen

Chigusa Morizane, MD
Hepatobiliary and Pancreatic Oncology Division
National Cancer Center Hospital
5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 (Japan)
Tel. +81 3 3542 2511, E-Mail cmorizan@ncc.go.jp

plasms that divides them into three tiers based on proliferation as follows [2]: (1) neuroendocrine tumor (NET) (G1): mitotic count <2 per 10 high power fields (HPF) and/or a Ki67 index of ≤2%; (2) NET (G2): mitotic count 2–20 per 10 HPF and/or a Ki67 index of 3–20%, and (3) neuroendocrine carcinoma (NEC): mitotic count >20 per 10 HPF and/or a Ki67 index of >20%. Among these classes, NEC is a poorly differentiated, high-grade malignant neoplasm. The definition of NEC refers to neoplasms previously classified as small-cell carcinoma or poorly differentiated (neuro)endocrine carcinoma (PDNEC). Since the first report of 'extrapulmonary oat cell carcinoma' of the mediastinum by Duguid and Kennedy [3] in 1930, extrapulmonary NECs (EP-NECs) have been reported to arise in a variety of organs, such as the gastrointestinal tract, pancreas, head and neck region, or urogenital tract [4–16]. EP-NECs are a fairly rare, heterogeneous disease entity, and no standard treatment has been established [17, 18]. Especially for extended or recurrent EP-NECs, treatment with combined etoposide and cisplatin, which is a representative regimen for the treatment of small-cell lung carcinoma (SCLC), has been mainly adopted [19–21] until now because these tumors share many features, including their immunohistochemical findings and aggressive clinical behavior [8]. However, some cytogenetic analyses have revealed differences between the two entities [6, 14, 22]. Therefore, EP-NECs may differ from SCLC with respect to their sensitivity to anticancer agents or patient outcome [7]. The aim of the present study was to clarify the efficacy of standard SCLC regimens when used for the treatment of advanced EP-NECs and to compare the outcome with that for SCLC. Moreover, we compared the sensitivity to systemic chemotherapy and the patient outcome according to the primary tumor site to identify prognostic factors.

Materials and Methods

Patients and Methods

This study was approved by the Ethics Committee of the National Cancer Center, Japan. The pathology records of the National Cancer Center Hospital, Tokyo, Japan (January 2000 to December 2008) were searched for neuroendocrine neoplasms. In all the patients, a fine-needle biopsy or surgical specimen had been used for the pathological diagnosis. Clinical information was obtained from the patients' medical records. Patients with EP-NEC or small-cell lung cancer according to the WHO classification [2, 23], chemotherapy-naïve patients with extended or recurrent disease, and patients treated with platinum-based combined chemotherapy [a regimen consisting of cisplatin and etoposide (PE regimen), cisplatin and irinotecan (IP regimen), or carboplatin and etoposide (CE regimen)] were considered for enrollment. If accurate proliferation fraction, such as Ki67 index or mitotic count, could not be obtained, tumor differentiation was diagnosed morphologically. In such cases, PDNECs according to the WHO 2004 [24] classification were considered as eligible. Patients who were participating in ongoing prospective clinical trials were excluded from the analysis. All the patients underwent computed tomography (CT) examinations to determine the tumor stage. CT scans of the brain or bone scans were also performed mainly in symptomatic patients. Upper and lower gastrointestinal endoscopic examinations were performed in patients with gastrointestinal NECs or unknown primary tumors. An extended NEC stage was defined as the presence of any single or multiple metastases at any distant anatomical site (including non-regional nodes), corresponding to the extended stage of the two-stage system for SCLC that was originally introduced by the Veterans' Administration Lung Study Group [25]. We investigated the patients' backgrounds, treatment efficacy, and the patient outcome according to the primary site. Thereafter, we compared the sensitivity to systemic chemotherapy and the patient outcome according to the primary tumor site to identify prognostic factors.

Study Design

The response to chemotherapy was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0 [26]. A response rate was defined as the sum of the complete response rate and the partial response rate. The χ^2 test was used to assess differences in the patient characteristics of the EP-NEC and SCLC groups and the relation between the primary tumor site and the response rate. Overall survival (OS) was calculated from the first day of treatment until the date of death or the last day of the follow-up period. In the univariate analysis, the cumulative survival proportions were calculated using the Kaplan-Meier method [27], and any differences were evaluated using the log-rank test. Only variables that achieved statistical significance in the univariate analysis were subsequently evaluated in the multivariate analysis using Cox's proportional hazards regression model [28]. A p value of <0.05 was considered statistically significant, and all the tests were two-sided. All statistical analyses were performed using the SPSS statistical software program package (SPSS version 11.0 for Windows).

Results

We retrospectively reviewed 981 patients with a pathologically confirmed diagnosis of neuroendocrine neoplasms (511 from extrapulmonary organs and 470 from the lung). Overall, 136 patients (41 with EP-NECs and 95 with SCLC) met the above-described criteria (fig. 1). The patient characteristics are summarized in table 1. The median age of the patients with EP-NECs was 58 years, which was significantly younger than that of the patients with SCLC (67 years). The patients included 26 males (63.4%) with EP-NECs and 75 males (78.9%) with SCLC; while the percentage of male subjects with EP-NECs was



Fig. 1. Study population. The target population of this study was patients with extended or recurrent extrapulmonary PDNECs or small-cell carcinoma who had been treated with chemotherapy (PE, IP or CE regimen) at our institute.

lower than that of male subjects with SCLC, the difference was not statistically significant. The majority of patients in both groups had a good performance status: 97.6% of the patients with EP-NECs and 90.5% of the patients with SCLC had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. Brain and lymph node metastases were observed more frequently among patients with SCLC than among those with EP-NECs ($p < 0.01$ and $p < 0.01$, respectively), whereas liver involvement was observed significantly more often among patients with EP-NECs than among those with SCLC ($p < 0.01$). The major primary sites of EP-NECs were the stomach in 10 patients, followed by the pancreas in 9 patients and the esophagus in 8 patients (table 2). We divided the patients with EP-NECs into three groups according to the primary tumor sites: the gastrointestinal tract group (GI tract group), comprising 43.9% of the EP-NECs; the liver, biliary tract or pancreas group (HBP group), comprising 39.0% of the EP-NECs, and the 'others' group (prostate, thymus, bladder, and unknown primary), comprising 17.1% of the EP-NECs. Patient characteristics are summarized in table 1. Overall, systemic chemotherapy was performed according to the PE regimen in 31 patients, the IP regimen in 70 patients, and the CE regimen in 35 patients (table 3). The tumor responses to chemotherapy are shown in table 4. The response rate was significantly higher in the SCLC group (77.8%) than in the EP-NEC group (30.8%; $p < 0.01$). Of the patients with EP-NECs, the response rate in the HBP group (12.5%) was significantly lower than that of the 'others' group (57.1%; $p = 0.025$) and tended to be lower than that in the GI group (37.5%; $p = 0.10$). The median survival time (MST) of the patients with EP-NECs was 9.2 months and had a tendency to be worse than that of SCLC patients with 13.6 months, but the difference was not significant ($p = 0.067$; fig. 2). The 1-year survival rate (61.1 vs. 38.6%) was better for the patients with SCLC than EP-NECs. And a few patients (11.8%) with SCLC but no patients with EP-NECs survived longer than 3 years. The MSTs of patients treated with an IP regimen, PE regimen, and CE regimen are shown in table 5. Of the patients with EP-NECs, the MSTs of the patients in the GI tract group, the HBP group, and the 'others' group were 14.9, 7.8, and 8.9 months, respectively ($p < 0.01$; fig. 3). The following 8 of the 15 pretreatment variables that were evaluated were identified as being significantly associated with the survival time in univariate analyses (table 6): ECOG PS ($p < 0.01$), primary site ($p < 0.01$), neuron-specific enolase (NSE; $p = 0.025$), hemoglobin ($p = 0.029$), albumin ($p < 0.01$), alkaline phosphatase ($p = 0.030$), liv-

Table 1. Clinical characteristics of the patients

	EP-NECs				SCLC	p value
	Total	GI tract group	HBP group	'Others' group		
Patients	41	18	16	7	95	
Age, years						<0.01*
Median	58	63.5	46.5	59	67	
Range	27–79	27–79	30–69	33–84	43–84	
Gender, n (%)						0.057**
Male	26 (63)	15 (83)	8 (50)	3 (43)	75 (79)	
Female	15 (37)	3 (17)	8 (50)	4 (57)	20 (21)	
EGOG PS, n (%)						0.28**
0	12 (29)	4 (22)	4 (25)	4 (57)	21 (21)	
1	28 (68)	14 (78)	11 (69)	3 (43)	65 (68)	
2	1 (2)	0	1 (6)	0	9 (9)	
NSE, ng/ml						0.050*
Median	43.8	34.2	127.7	14.6	57.2	
Range	7.5–1,930	9.2–210.5	20.7–1930	7.5–571.0	5.5–1,158	
ProGRP, pg/ml						0.69*
Median	43.0	47.9	31.3	48.9	668.4	
Range	5.3–63,090	5.3–13,810	11.9–63,090	21.2–117.1	18.3–40,550	
Metastatic site, n (%)						
Liver	30 (73)	14 (78)	13 (81)	3 (43)	21 (22)	<0.01**
Brain	2 (5)	1 (6)	0	1 (14)	27 (28)	<0.01**
Bone	4 (10)	1 (6)	1 (6)	2 (29)	22 (23)	0.068**
Lung	5 (12)	1 (6)	3 (19)	1 (14)	–	–
Lymph node	21 (51)	13 (72)	5 (31)	0	76 (80)	<0.01**

ProGRP = Pro-gastrin-releasing peptide. * Student's t test, ** χ^2 test.



Fig. 2. Kaplan-Meier plot of OS. The MST of the patients with EP-NECs was 9.2 months and had a tendency to be shorter than that of patients with SCLC, which was 13.6 months. * log-rank test.

Table 2. Primary tumor site of the patients with EP-NECs

GI tract group	
Stomach	10
Esophagus	8
HBP group	
Pancreas	9
Gallbladder	4
Liver	3
'Others' group	
Thymus	2
Prostate	2
Bladder	2
CUP	2

CUP = Carcinoma of unknown primary site.

Table 3. Chemotherapy regimens

	EP-NECs				SCLC	Total
	Total	GI tract	HBP	Others		
CDDP + VP-16	18	1	16	1	13	31
CDDP + CPT-11	22	17	0	5	48	70
CBDCA + VP-16	1	0	0	1	34	35
Total	41	18	16	7	104	136

CDDP = Cisplatin; VP-16 = etoposide; CPT-11 = irinotecan; CBDCA = carboplatin.

Table 4. Tumor responses

	EP-NECs				SCLC
	Total	GI tract	HBP	Others	
Complete response	1	0	0	1	5
Partial response	11	6	2	3	72
Stable disease	17	6	9	2	7
Progressive disease	10	4	5	1	48
Not evaluable	2	2	0	0	6
Response rate	30.8%	37.5%	12.5%	57.1%	77.8%
			p = 0.10*	p = 0.025*	
			p < 0.01*		(RECIST version 1.0)

* χ^2 test.

Table 5. The MSTs of the patients treated with IP regimen, PE regimen, and CE regimen

	EP-NECs			SCLC			Total		
	n	MST		n	MST		n	MST	
CDDP + VP-16	18	7.3	p = 0.001*	13	12.4	p = 0.023*	31	8.9	p < 0.001*
CDDP + CPT-11	22	14.9		48	16.6		70	16.6	
						p = 0.023*			p = 0.038*
CBDCA + VP-16	1	16.9		34	9.3		35	9.3	

CDDP = Cisplatin; VP-16 = etoposide; CPT-11 = irinotecan; CBDCA = carboplatin. * log-rank test.

Table 6. Prognostic factors (univariate analysis)

	n	Median OS ± SE months	p*
Age			
≥64 years	66	12.5 ± 0.97	0.66
<64 years	70	12.9 ± 2.07	
Sex			
Male	101	12.4 ± 0.99	0.74
Female	35	12.9 ± 1.34	
ECOG PS			
0–1	126	13.5 ± 1.64	<0.01
2–3	10	5.1 ± 3.02	
Primary site			
Lung	95	13.6 ± 0.33	<0.01
GI tract	18	14.9 ± 8.03	
HBP	16	7.8 ± 1.49	
Others	7	8.9 ± 3.52	
NSE			
≥15 ng/ml	118	12.1 ± 1.55	0.025
<15 ng/ml	18	26.2 ± 5.05	
ProGRP			
≥45 pg/ml	97	13.3 ± 1.35	0.83
<45 pg/ml	39	12.4 ± 1.42	
Hb			
≥12 g/dl	85	13.7 ± 0.40	0.029
<12 g/dl	51	10.3 ± 1.96	
CRP			
≥0.4 mg/dl	89	11.3 ± 1.69	0.056
<0.4 mg/dl	47	14.9 ± 1.82	
Alb			
≥3.7 g/dl	72	14.6 ± 1.40	<0.01
<3.7 g/dl	64	9.3 ± 0.43	
ALP			
≥360 IU/l	37	9.2 ± 0.68	0.030
<360 IU/l	99	13.8 ± 0.88	
LDH			
≥230 IU/l	103	11.6 ± 1.86	0.058
<230 IU/l	33	18.0 ± 5.54	
Brain metastases			
Presence	29	12.4 ± 0.55	0.66
Absence	107	13.6 ± 0.97	
Bone metastases			
Presence	26	10.4 ± 3.72	0.078
Absence	110	13.6 ± 0.36	
Liver metastases			
Presence	51	9.1 ± 0.35	<0.01
Absence	85	14.1 ± 1.46	
Regimen			
CDDP + VP-16	31	8.9 ± 0.66	<0.01
CBDCA + VP-16	35	9.3 ± 1.45	
CDDP + CPT-11	70	16.6 ± 4.38	

ProGRP = Pro-gastrin-releasing peptide; Hb = hemoglobin; CRP = C-reactive peptide; Alb = albumin; ALP = alkaline phosphatase; LDH = lactate dehydrogenase; CDDP = cisplatin; VP-16 = etoposide; CBDCA = carboplatin; CPT-11 = irinotecan. * log-rank test.



Fig. 3. Kaplan-Meier curves of OS of the patients with EP-NECs. The MSTs of the patients in the GI tract group, the HBP group, and the 'others' group were 14.9, 7.8, and 8.9 months, respectively. The HBP group had the worst prognosis. * log-rank test.

er involvement ($p < 0.01$), and chemotherapy regimen ($p < 0.01$). Only 3 of the above factors were identified as independent unfavorable prognostic factors in a multivariate Cox regression model: an ECOG PS of 2 or 3 (hazard ratio 3.786; $p < 0.01$), liver involvement (hazard ratio 1.943; $p = 0.013$), and the PE regimen (hazard ratio compared with the IP regimen 1.990; $p = 0.032$; table 7).

Discussion

The definition of NET has been confused for a long time, and the clinical and pathologic features of NETs have been described by many investigators, with most studies focusing on subsets of tumors restricted to one organ or organ system. Site-longitudinal grading, staging, and classification systems have been developed by the WHO [2, 23] and the European Neuroendocrine Tumor Society (ENETS) [29, 30]. Among the parameters of those classification systems, the proliferative index has emerged as a fundamental grading characteristic that now appears in most major schemata. Within these schemata, NECs represent the highest grade of malignancy, and patients with these tumor types have the worst outcome among all patients with neuroendocrine neoplasms [31, 32]. Therefore, the development of an effective therapy for this disease entity is essential.

Systemic chemotherapy for patients with EP-NECs has been conducted according to the regimens used for